Annette S. Little - Concepedia

Author

Annette S. Little

Babraham Institute

Also Known As

A S Little, A.S. Little, Annette Little, Annette S Little, Annette S. Little, Annette S. Little

Publications

654

Citations

H-Index

Concepts

All Affiliations

Babraham Institute Horizon Discovery (United Kingdom)AstraZeneca (United Kingdom)

About

Annette S. Little is an author at Babraham Institute specializing in tumor biology, cancer research, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	164
2	Cell Biology	2	2	164
3	Health Sciences	1	1	23
4	Cell Signaling	1	1	141
5	Drug Resistance	1	1	23

Annette S. Little

Publications

544

Citations

H-Index

Page 1

	Year	Citations
Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells Annette S. Little, Kathryn Balmanno, Matthew J. Sale, Science Signaling	2011	204
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance Victoria Chell, Kathryn Balmanno, Annette S. Little, Oncogene Gatekeeper MutationCell SignalingReceptor Tyrosine KinaseFibroblast Growth FactorCell Biology	2012	141
Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance Carlos le Sage, Steffen Lawo, Prince Panicker, Scientific Reports	2017	61
A Correction to the Research Article Titled: “Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells” by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook Annette S. Little, Kathryn Balmanno, Matthew J. Sale, Science Signaling	2011	44
Increasing the performance of pooled CRISPR–Cas9 drop-out screening Benedict C. S. Cross, Steffen Lawo, C Archer, Scientific Reports	2016	44
Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling Chia-Wen Hsu, Ruili Huang, Thai Khuc, Oncotarget	2016	27
Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling Annette S. Little, Kathryn Balmanno, Matthew J. Sale, Biochemical Society Transactions Chemoprevention StrategyCancer BiologyTumor BiologyDrug ResistanceReceptor Tyrosine Kinase	2012	23

Page 1